Skin disorders and sleep in adults: Where is the evidence?

Sleep Medicine Reviews

Volumn 14, Issue 6, 2010, Pages 351-358

  Thorburn, Patrick T ^a   Riha, Renata L ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Randomised controlled trial (RCT); Skin disorders; Sleep; Treatment

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CETIRIZINE; CHINESE DRUG; CLONAZEPAM; CLONIDINE; DESLORATADINE; DIPHENHYDRAMINE; DOXEPIN; EMOLLIENT AGENT; FEXOFENADINE; HYPNOTIC AGENT; INDINAVIR; MELATONIN; MIRTAZAPINE; MONTELUKAST; NEUROLEPTIC AGENT; NITRAZEPAM; OLANZAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; STEROID; TEMAZEPAM; TRIAZOLAM; ZOLPIDEM; ZOPICLONE;

ADULT; ANXIETY DISORDER; ATOPIC DERMATITIS; CHRONIC URTICARIA; CIRCADIAN RHYTHM; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; EVENING DOSAGE; HUMAN; INFESTATION; INSOMNIA; LIPODYSTROPHY; PATHOPHYSIOLOGY; PRURITUS; PSORIASIS; PSYCHOLOGICAL ASPECT; REVIEW; SCRATCHING; SKIN DISEASE; SLEEP APNEA SYNDROME; SLEEP DEPRIVATION; SLEEP DISORDER; URTICARIA;

ADULT; COMORBIDITY; DERMATITIS; HUMANS; LIPODYSTROPHY, FAMILIAL PARTIAL; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SKIN DISEASES; SLEEP; SLEEP APNEA, OBSTRUCTIVE; SLEEP DISORDERS; URTICARIA;

EID: 77957863711     PISSN: 10870792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smrv.2009.12.001     Document Type: Review

References (94)

1. Hon K.L., Leung T.F., Wong Y., Fok T.F. Lesson from performing SCORADs in children with atopic dermatitis: subjective symptoms do not correlate well with disease extent or intensity. Int J Dermatol 2006, 45:728-730.
2. Yosipovitch G., Xiong G.L., Haus E., Sackett-Lundeen L., Ashkenazi I., Maibach H.I. Time-dependent variations of the skin barrier function in humans: transepidermal water loss, stratum corneum hydration, skin surface pH, and skin temperature. J Invest Dermatol 1998, 110:20-23.
3. Lee C.H., Chuang H.Y., Shih C.C., Jong S.B., Chang C.H., Yu H.S. Transepidermal water loss, serum IgE and beta-endorphin as important and independent biological markers for development of itch intensity in atopic dermatitis. Br J Dermatol 2006, 154:1100-1107.
4. Yosipovitch G. Dry skin and impairment of barrier function associated with itch - new insights. Int J Cosmet Sci 2004, 26:1-7.
5. Yosipovitch G., Goon A., Wee J., Chan Y.H., Goh C.L. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000, 143:969-973.
6. Cormia F.E. Experimental histamine pruritus. Influence of physical and psychological factors on threshold reactivity. J Invest Dermatol 1952, 19:21-34.
7. Hanifin J.M. Pharmacophysiology of atopic dermatitis. Clin Rev Allergy 1986, 4:43-65.
8. Hadley M.E. Adrenal steroid hormones. Endocrinology 2000, 362-394. Prentice Hall, New Jersey. 5th ed.
9. Barnes P., FitzGerald G., Brown M., Dollery C. Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol. N Engl J Med 1980, 303:263-267.
10. Krishnan A., Koo J. Psyche, opioids, and itch: therapeutic consequences. Dermatol Ther 2005, 18:314-322.
11. Gelder M., Mayou R., Geddes J. Mood disorders. Psychiatry 2005, 97-118. Oxford University Press, Oxford. 3rd ed.
12. Shvartzman P. Pain management. Saunders manual of medical practice 2000, 43-45. WB Saunders, Philadelphia, PA. R. Rakel (Ed.).
13. Ostlere L.S., Cowen T., Rustin M.H. Neuropeptides in the skin of patients with atopic dermatitis. Clin Exp Dermatol 1995, 20. 462-447.
14. Boguniewicz M. Atopic dermatitis: beyond the itch that rashes. Review. Immunol Allergy Clin North Am 2006, 25:333-351. vii.
15. Leung D.Y., Nicklas R.A., Li J.T., Bemstein I.L., Blessing-Moore J., Boguniewicz M., et al. Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2004, 93(3 Suppl. 2):S1-21.
16. Chamlin S.L., Mattson C.L., Frieden I.J., et al. The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis. Arch Pediatr Adolesc Med 2005, 159:745-750.
17. Bender B.G., Leung S.B., Leung D.Y. Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: an objective life quality measure. J Allergy Clin Immunol 2003, 111:598-602.
18. Berth-Jones J., Takwale A., Tan E., et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002, 147:324-330.
19. Ebata T., Izumi H., Aizawa H., Kamide R., Niimura M. Effects of nitrazepam on nocturnal scratching in adults with atopic dermatitis: a double-blind placebo-controlled crossover study. Br J Dermatol 1998, 138:631-634.
20. Schäfer T. Epidemiology of psoriasis. Review and the German perspective. Review. Dermatology 2006, 212:327-337.
21. Barker J.N. Genetic aspects of psoriasis. Review. Clin Exp Dermatol 2001, 26:321-325.
22. Skov L., Baadsgaard O. Bacterial superantigens and inflammatory skin diseases. Review. Clin Exp Dermatol 2000, 25:57-61.
23. Gupta M.A., Gupta A.K., Kirkby S., et al. A psychocutaneous profile of psoriasis patients who are stress reactors. A study of 127 patients. Gen Hosp Psychiatry 1989, 11:166-173.
24. Zachariae R., Zachariae H., Blomqvist K., et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 2002, 146:1006-1016.
25. Krueger G.G., Feldman S.R., Camisa C., et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?. J Am Acad Dermatol 2000, 43(2 Pt 1):281-285.
26. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996, 14:485-496.
27. Ramsay B., O'Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol 1988, 118:195-201.
28. Fried R.G., Friedman S., Paradis C., et al. Trivial or terrible? The psychosocial impact of psoriasis. Int J Dermatol 1995, 34:101-105.
29. Gupta M.A., Gupta A.K. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998, 139:846-850.
30. McKenna S.P., Cook S.A., Whalley D., et al. Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol 2003, 149:323-331.
31. Sampogna F., Gisondi P., Melchi C.F., Amerio P., Girolomoni G., Abeni D. IDI Multipurpose Psoriasis Research on Vital Experiences Investigators. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004, 151:594-599.
32. Russo P.A., Ilchef R., Cooper A.J. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol 2004, 45:155-159. quiz 160-161.
33. Dorland's medical dictionary for health consumers 2007, Saunders.
34. Meinking T.L., Taplin D., Hermida J.L., Pardo R., Kerdel F.A. The treatment of scabies with ivermectin. N Engl J Med 1995, 333:26-30.
35. Green M. Epidemiology of scabies. Epidemiol Rev 1989, 11:126-150.
36. Strong M., Johnstone P.W. Interventions for treating scabies. Review. Cochrane Database Syst Rev 2007, 18. CD000320.
37. Grattan C.E.H., Black A.K. Urticaria and Angioedema. Dermatology 2003, vol. 1:287-302. Edinburgh: Mosby. J.L. Bologne, J.L. Jorizzo, R.P. Rapini (Eds.).
38. Yosipovitch G., Ansari N., Goon A., Chan Y.H., Goh C.L. Clinical characteristics of pruritus in chronic idiopathic urticaria. Br J Dermatol 2002, 147:32-36.
39. O'Donnell B.F., Lawlor F., Simpson J., Morgan M., Greaves M.W. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997, 136:197-201.
40. Soter N.A. Acute and chronic urticaria and angioedema. J Am Acad Dermatol 1991, 25:146-154.
41. Schwartz L.B. Mast cells and their role in urticaria. J Am Acad Dermatol 1991, 25:190-204.
42. Rickels K., Morris R.J., Newman H., Rosenfeld H., Schiller H., Weinstock R. Diphenhydramine in insomniac family practice patients: a double-blind study. J Clin Pharmacol 1983, 23:234-242.
43. Hayes D. Obstructive sleep apnea in a patient with basal cell nevus syndrome. J Ky Med Assoc 2006, 104:291-292.
44. Hanson R.D., Olsen K.D., Rogers R.S. Upper aerodigestive tract manifestations of cicatricial pemphigoid. Ann Otol Rhinol Laryngol 1988, 97:493-499.
45. Scalf L.A., Fowler J.F. Allergic contact dermatitis caused by dialkyl thioureas in a patient with sleep apnea. Am J Contact Dermat 1999, 10(3):169-171.
46. Dunnigan M.G., Cochrane M.A., Kelly A., Scott J.W. Familial lipoatrophic diabetes with dominant transmission. A new syndrome. Q J Med 1974, 43:33-48.
47. Garg A. Lipodystrophies. Am J Med 2000, 108:143-152.
48. Hegele R.A., Al-Attar S.A., Rutt B.K. Obstructive sleep apnea in 2 women with familial partial lipodystrophy due to a heterozygous LMNA R482Q mutation. Can Med Assoc J 2007, 177:743-745.
49. Saint-Marc T., Partisani M., Poizot-Martin I., et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999, 13:1659-1667.
50. Carr A., Cooper D.A. Adverse effects of antiretroviral therapy. Lancet 2000, 356(9239):1423-1430.
51. Schulz R., Lohmeyer J., Seeger W. Obstructive sleep apnea due to HIV-associated lipodystrophy. Clin Infect Dis 2003, 37. 1398-1389.
52. Epstein L.J., Strollo P.J., Donegan R.B., Delmar J., Hendrix C., Westbrook P.R. Obstructive sleep apnea in patients with human immunodeficiency virus (HIV) disease. Sleep 1995, 18:368-376.
53. Young T., Palta M., Dempsey J., Skatrud J., Weber S., Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993, 29(328):1230-1235.
54. Lo Re V., Schutte-Rodin S., Kostman J.R. Obstructive sleep apnoea among HIV patients. Int J STD AIDS 2006, 17:614-620.
55. American Academy of Sleep Medicine International classification of sleep disorders: diagnostic and coding manual 2005, American Academy of Sleep Medicine, Westchester, IL. 2nd ed.
56. Murtagh D.R., Greenwood K.M. Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin Psychol 1995, 63:79-89.
57. Smith M.T., Perlis M.L., Park A., et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2002, 159:5-11.
58. Morin C.M., Culbert J.P., Schwartz S.M. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 1994, 151:1172-1180.
59. Riemann D., Perlis M.L. The treatments of chronic insomnia: a review of benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep Med Rev 2009, 13(3):205-214.
60. van Straten A., Cuijpers P. Self-help therapy for insomnia: a meta-analysis. Sleep Med Rev 2009, 13(1):61-71.
61. Krystal A.D. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev 2009, 13(4):265-274.
62. Kudo Y., Kurihara M. Clinical evaluation of diphenhydramine hydrochloride for the treatment of insomnia in psychiatric patients: a double-blind study. J Clin Pharmacol 1990, 30:1041-1048.
63. Kelsay K. Management of sleep disturbance associated with atopic dermatitis. J Allergy Clin Immunol 2006, 118:198-201.
64. Buscemi N, Vandermeer B, Pandya R, et al. Agency for Healthcare Research and Quality; Melatonin for Treatment of Sleep Disorders. Evidence Report/Technology Assessment No. 108, 2004.
65. Ming X., Gordon E., Kang N., Wagner G.C. Use of clonidine in children with autism spectrum disorders. Brain Dev 2008, 30:454-460.
66. Kratochvil C.J. Pharmacological management of treatment-induced insomnia in ADHD. Review. J Am Acad Child Adolesc Psychiatry 2005, 44:499-501.
67. Darsow U., Scharein E., Bromm B., Ring J. Skin testing of the pruritogenic activity of histamine and cytokines (interleukin-2 and tumour necrosis factor-alpha) at the dermal-epidermal junction. Br J Dermatol 1997, 137:415-417.
68. Wahlgren C.F., Tengvall Linder M., Hägermark O., Scheynius A. Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects. Arch Dermatol Res 1995, 287:572-580.
69. Lissoni P., Rovelli F., Brivio F., Brivio O., Fumagalli L. Circadian secretions of IL-2, IL-12, IL-6 and IL-10 in relation to the light/dark rhythm of the pineal hormone melatonin in healthy humans. Nat Immun 1998, 16:1-5.
70. Lippert U., Hoer A., Möller A., Ramboer I., Cremer B., Henz B.M. Role of antigen-induced cytokine release in atopic pruritus. Int Arch Allergy Immunol 1998, 116:36-39.
71. Ständer S., Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Review. Exp Dermatol 2002, 11:12-24.
72. Takaoka A., Arai I., Sugimoto M., et al. Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis. Exp Dermatol 2006, 15:161-167.
73. Sonkoly E., Muller A., Lauerma A.I., et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006, 117:411-417.
74. Steinhoff M., Bienenstock J., Schmelz M., Maurer M., Wei E., Bíró T. Neurophysiological, neuroimmunological and neuroendocrine basis of pruritus. Review. J Invest Dermatol 2006, 126:1705-1718.
75. Onigbogi O., Ajayi A.A., Ukponmwan O.E. Mechanisms of chloroquine-induced body-scratching behavior in rats: evidence of involvement of endogenous opioid peptides. Pharmacol Biochem Behav 2000, 65:333-337.
76. Andrew D., Craig A.D. Spinothalamic lamina I neurones selectively responsive to cutaneous warming in cats. J Physiol 2001, 537:489-495.
77. Ikoma A., Rukwied R., Ständer S., Steinhoff M., Miyachi Y., Schmelz M. Neurophysiology of pruritus: cutaneous elicitation of itch. Review. Arch Dermatol 2003, 139:1463-1470.
78. Blunk J.A., Schmelz M., Zeck S., Skov P., Likar R., Koppert W. Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: an in vivo microdialysis study in human skin. Anesth Analg 2004, 98:364-370.
79. Bigliardi-Qi M., Lipp B., Sumanovski L.T., Buechner S.A., Bigliardi P.L. Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatology 2005, 210:91-99.
80. Labrecque G., Vanier M.C. Biological rhythms in pain and in the effects of opioid analgesics. Review. Pharmacol Ther 1995, 68:129-147.
81. Yosipovitch G., Yosipovitch Z., Harell D., Ashkenazi I., Erman A. Diurnal rhythm of prostanoid secretion from bone/marrow organ in the rat. Bone 1995, 17:79-83.
82. Honma Y., Arai I., Hashimoto Y., et al. Prostaglandin D2 and prostaglandin E2 accelerate the recovery of Cutaneous barrier disruption induced by mechanical scratching in mice. Eur J Pharmacol 2005, 25(518):56-62.
83. Friedmann P.S., Palmer R., Tan E., et al. A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. Clin Exp Allergy 2007, 37:1536-1540.
84. Pittler M.H., Armstrong N.C., Cox A., Collier P.M., Hart A., Ernst E. Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis. Br J Dermatol 2003, 148:307-313.
85. Hannuksela M., Kalimo K., Lammintausta K., et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy 1993, 70:127-133.
86. Sheehan M.P., Rustin M.H., Atherton D.J., et al. Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet 1992, 340(8810):13-17.
87. Monroe E., Finn A., Patel P., Guerrero R., Ratner P., Bernstein D. Desloratadine Urticaria Study Group. Efficacy and safety of desloratadine 5mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2003, 48:535-541.
88. Ring J., Hein R., Gauger A., Bronsky E., Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001, 40:72-76.
89. Grob J.J., Auquier P., Dreyfus I., Ortonne J.P. Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. J Eur Acad Dermatol Venereol 2008, 22(1):87-93.
90. Pacor M.L., Di Lorenzo G., Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001, 31:1607-1614.
91. Finn A.F., Kaplan A.P., Fretwell R., Qu R., Long J. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999, 104:1071-1078.
92. Nelson H.S., Reynolds R., Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000, 84:517-522.
93. Sharpe G.R., Shuster S. The effect of cetirizine on symptoms and wealing in dermographic urticaria. Br J Dermatol 1993, 129:580-583.
94. Hanifin J.M., Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980, Suppl 92:44-47.